Ra Medical Systems Adds Additional Clinical and Sales Representatives
02/01/2023 - 09:20 AM
Catheter Precision Expands its VIVO™ Product into New Territories in the US
FORT MILL, SC / ACCESSWIRE / February 1, 2023 / Ra Medical Systems, Inc. (NYSE American:RMED) (Ra Medical), a medical device and technology company focused on cardiac electrophysiology, announces that additional representatives have been hired to support its VIVO technology in new territories within the United States. VIVO, developed by Ra Medical's wholly owned subsidiary Catheter Precision, is a proprietary AI system used to non-invasively identify the origin of ventricular arrhythmias prior to an ablation procedure.
"We are excited to add to our clinical support team and begin the first steps of building an in-house sales team," said David Jenkins, Ra Medical Executive Chairman. "These additional employees allow us to expand our footprint into new territories that are influential in the electrophysiology space such as Texas and Ohio. We believe that supporting the VIVO product both through direct sales and additional clinical support will provide us with additional opportunities for physician partnerships and further innovation."
To date, VIVO has only been available to select physicians as part of a limited launch. Hiring additional support, in increments by territories, is a part of the launch strategy established by Catheter Precision to ensure positive clinical adoption and an increase in utilization in 2023.
About VIVO
About Ra Medical Systems
CONTACTS: At the Company mhuck@catheterprecision.com
SOURCE: Ra Medical Systems, Inc.
https://www.accesswire.com/737625/Ra-Medical-Systems-Adds-Additional-Clinical-and-Sales-Representatives
RMED Rankings
N/A Ranked by Stock Gains
RMED Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Carlsbad
About RMED
advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients’ quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of
